| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6395767 | ASTRAZENECA AB | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
Feb, 2021
(3 years ago) | |
| USRE44186 | ASTRAZENECA AB | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
Jul, 2023
(9 months ago) | |
| US7951400 | ASTRAZENECA AB | Coated tablet formulation and method |
Nov, 2028
(4 years from now) | |
Onglyza is owned by Astrazeneca Ab.
Onglyza contains Saxagliptin Hydrochloride.
Onglyza has a total of 3 drug patents out of which 2 drug patents have expired.
Expired drug patents of Onglyza are:
- US6395767
- USRE44186
Onglyza was authorised for market use on 31 July, 2009.
Onglyza is available in tablet;oral dosage forms.
Onglyza can be used as method for treating type ii diabetes by administering saxagliptin.
Drug patent challenges can be filed against Onglyza from 31 July, 2013.
The generics of Onglyza are possible to be released after 30 November, 2028.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-134) | May 24, 2016 |
| M(M-175) | Apr 05, 2019 |
| M(M-198) | Feb 27, 2020 |
| New Chemical Entity Exclusivity(NCE) | Jul 31, 2014 |
| M(M-108) | Dec 16, 2014 |
Drugs and Companies using SAXAGLIPTIN HYDROCHLORIDE ingredient
NCE-1 date: 31 July, 2013
Market Authorisation Date: 31 July, 2009
Treatment: Method for treating type ii diabetes by administering saxagliptin
Dosage: TABLET;ORAL
ONGLYZA family patents
